CABACabaletta Bio
About Cabaletta Bio
Cabaletta Bio (NASDAQ:CABA) focuses on developing therapies aimed at providing a functional cure for patients with autoimmune diseases. Its approach centers on utilizing engineered T cell therapies targeting B cell-mediated autoimmune diseases, leveraging its proprietary technology to specifically target and eliminate the cells responsible for disease activity. The company's pipeline includes several projects at various stages of development, targeting a range of autoimmune disorders with the objective of achieving long-term disease remission or functional cure. Cabaletta Bio aims to transform the treatment landscape for autoimmune disease patients, offering new hope through innovative, targeted therapies.
What is CABA known for?
Snapshot
Public US
Ownership
2017
Year founded
118
Employees
Philadelphia, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Philadelphia, US
Products and/or services of Cabaletta Bio
- DesCAARTes™ platform harnesses Chimeric AutoAntibody Receptor T cells designed to target and eliminate B cells causing autoimmune diseases.
- Dsg3-CAART is a therapy aimed at treating mucosal pemphigus vulgaris by selectively targeting and depleting disease-causing B cells.
- FVIII-CAART seeks to provide a potential treatment for hemophilia A by using engineered T cells to eliminate inhibitors of factor VIII.
- MuSK-CAART therapy is being developed for patients with MuSK myasthenia gravis, targeting specific B cells to alleviate symptoms.
- The collaboration with the University of Pennsylvania explores novel CAART therapies for autoimmune diseases by leveraging genetic engineering expertise and clinical insights.
- CART-TT focuses on T cell-mediated therapies to potentially treat T cell-related autoimmune and inflammatory diseases, offering a unique approach by targeting specific T cell subsets.
Cabaletta Bio executive team
- Dr. Steven A. Nichtberger M.D.Co-Founder, Chairman, CEO & President
- Dr. David J. Chang FACR, M.D., M.P.H.Chief Medical Officer
- Dr. Gwendolyn K. Binder Ph.D.President of Science & Technology
- Dr. Michael C. Milone M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Dr. Aimee Payne M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Mr. Anup Marda M.B.A.Chief Financial Officer
- Dr. Qing Sarah Yuan Ph.D.Chief Technology Officer
- Dr. Samik Basu M.D.Chief Scientific Officer
- Mr. Michael Gerard J.D.General Counsel & Secretary
- Ms. Heather Harte-Hall M.Sc.Chief Compliance Officer